Glaxo's In-Licensing Binge Continues
The message of GSK's recent $270 million dollar licensing deal with Adolor is that, so long as Big Pharma pipelines are suffering and patents keep expiring, late-stage products from small companies can command highly respectable prices. And GSK’s active dealmaking shows that this company, unlike many of its competitors, recognizes that late-stage products still carry enormous risk.
You may also be interested in...
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.